Fresenius Kabi introduces a new cost-effective generic option, Cetrorelix Acetate for Injection, expanding its women’s health portfolio as a therapeutic equivalent to EMD Serono’s Cetrotide. The company aims to offer comprehensive and affordable treatment choices for women’s health in the U.S. Visit Fresenius Kabi’s website for more details.